30 closest matches · ranked by relevance
Severe Hepatic Veno-Occlusive Disease
Primary: Survival at Day+100 Following Hematopoietic Stem Cell Transplant — 38.2; 25.0 percentage of participants
Hepatic Veno-Occlusive Disease
Primary: Survival by Day+100 Post Stem Cell Transplant or Chemotherapy — 49.9 Percentage of participants alive
Veno-occlusive Disease
Primary: Veno-occlusive Disease (VOD)-Free Survival by Day +30 Post-Hematopoietic Stem Cell Transplant (HSCT) Per the Independent Endpoint Adjudication Committee (EPAC) — 66.8…
Sinusoidal Obstruction Syndrome · Complications of Bone Marrow Transplant
Primary: Sensitivity and Specificity of US for VOD/SOS — 80; 93 percentage of participants
Niemann-Pick Disease, Type C
Primary: Efficacy of Adrabetadex (VTS-270) to Reduce Plasma Levels of a Conjugated Bile Acid, Known as 5α-cholanic Acid-3β, 5α, 6β-triol N-(Carboxymethyl)-Amide — 32.6; 87.9 ng/ml
Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 94.9; 92.0; 100.0; 93.8 percentage of participants
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 77.8 Percentage of participants
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 83.3; 94.3; 87.8 percentage of participants…
Hepatitis C, Chronic
Primary: SVR12: Plasma HCV RNA Level Less Than 25 IU/mL at 12 Weeks After End of Treatment (EOT) — 61.1; 52.9 Percentage of participants
Cancer
Primary: Maximum Observed Plasma Concentration and Concentration at Steady-state Following Multiple Doses of Vismodegib — 23.6; 30.7; 30.5; 20.5 micromolar
Thrombotic Microangiopathies
Primary: Percent of Total Doses of Defibrotide That Were Missed [Feasibility] — 0.7 percentage of missed doses
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 92.2; 92.2 Percentage of participants — p=<0.001
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12) — 96.2 percentage of participants
Severe Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of Dacomitinib — 9.673; 7.389 nanogram per milliliter
Hepatitis C · Liver Transplantation
Primary: Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted…
Hepatorenal Syndrome
Primary: Improvement of Renal Function (SCr) From Day 1 Thru End of Treatment, Repeated Measure Analysis. SCr Will be Collected Daily, From Day 1 Thru End of Treatment. Baseline…
Liver Fibrosis · Hepatic Fibrosis · Liver Cirrhosis
Primary: Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score — 25; 14 participants — p=0.73
Hepatic Insufficiency
Primary: AUC (0-inf) of Nintedanib — 200; 674; 92.7; 77.8 ng*h/mL
Prophylaxis Of Invasive Fungal Infections
Primary: Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit — 3 participants
Carcinoma, Hepatocellular
Primary: Tumour Stabilisation Rate — 5.3; 16.0; 8.7 percentage of patients
Polycystic Kidney, Autosomal Dominant · Polycystic Liver Disease · Hepatomegaly
Primary: Percent Change in Liver Volume — -5.0; 0.9 percent change — p=0.048
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 78.1; 72.2; 80.0; 85.7 percentage of participants
Myelodysplastic Syndrome
Primary: Dosage Determination for IV-infusion of Vosaroxin in Int-2 or High-risk Mds — 200 mg/m^2
Liver Disease
Primary: Results of HepQuant SHUNT Test: Elimination Rate (IV Phase 1 Only; Min-1) — 0.104; 0.092; 0.099 min-1
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Change in D-dimer — 478.8; 260.1 ng/mL
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Severe Hepatic Impairment · Healthy
Primary: Pharmacokinetic Parameters of MCI-186: Peak Drug Concentration (Cmax) — 347.6; 280.3 ng/mL
Hepatitis C Virus
Primary: Pharmacokinetic (PK) Parameter of Velpatasvir: AUClast — 5597.8; 7971.7 h*ng/mL
Von Hippel-Lindau Syndrome
Primary: Tabulation of Adverse Events — 13 adverse events
HCV Infection
Primary: Pharmacokinetic (PK) Parameter of Voxilaprevir: AUClast — 2058.5; 3872.5; 500.1; 601.2 h*ng/mL